Publication Name	World Journal of Gastroenterology
Manuscript ID	100804
Country	United States

Received	2024-08-27 08:40
Peer-Review Started	2024-09-05 02:15
To Make the First Decision
Return for Revision	2024-10-11 03:37
Revised	2024-10-24 17:10
Second Decision	2024-11-12 02:36
Accepted by Journal Editor-in-Chief
Accepted by Executive Editor-in-Chief	2024-11-12 06:28
Articles in Press	2024-11-12 06:28
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2024-11-15 00:54
Publish the Manuscript Online	2024-11-29 08:40

ISSN	1007-9327 (print) and 2219-2840 (online)
Open Access	This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Copyright	© The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Gastroenterology & Hepatology
Manuscript Type	Letter to the Editor
Article Title	GLP-1, GIP/GLP-1, and GCGR/GLP-1 receptor agonists: Novel therapeutic agents for metabolic dysfunction-associated steatohepatitis
Manuscript Source	Invited Manuscript
All Author List	Anmol Singh, Aalam Sohal and Akash Batta
ORCID	Author(s) ORCID Number Aalam Sohal http://orcid.org/0000-0001-8365-7240 Akash Batta http://orcid.org/0000-0002-7606-5826
Funding Agency and Grant Number
Corresponding Author	Akash Batta, Assistant Professor, MD, Department of Cardiology, Dayanand Medical College and Hospital, Tagore Nagar, Civil Lines, Ludhiana 141001, Punjab, India. akashbatta02@gmail.com
Key Words	Glucagon-like peptide-1 receptor agonists; Metabolic dysfunction-associated steatotic liver disease; Metabolic dysfunction-associated steatohepatitis; Liver fibrosis; Semaglutide; Tirzepatide; Survodutide
Core Tip	Metabolic dysfunction-associated steatotic liver disease (MASLD) affects 1/3rd of the global population, leading to significant morbidity and mortality. GLP-1 agonists may decrease the risk of progression of MASLD by reducing fatty acid oxidation and cytokine production. GLP-1/GIP receptor agonists (RA) (tirzepatide) and Glucagon/GLP-1 RA (survodutide, efinopegdutide and pemvidutide), have also shown promising results in resolving metabolic dysfunction-associated steatohepatitis (MASH) and demonstrating histological improvement in liver fibrosis. The advancing field of MASH management points to a promising future, with combination therapies likely to significantly improve patient outcomes.
Publish Date	2024-11-29 08:40
Citation	<p>Singh A, Sohal A, Batta A. GLP-1, GIP/GLP-1, and GCGR/GLP-1 receptor agonists: Novel therapeutic agents for metabolic dysfunction-associated steatohepatitis. <i>World J Gastroenterol</i> 2024; 30(48): 5205-5211</p>
URL	https://www.wjgnet.com/1007-9327/full/v30/i48/5205.htm
DOI	https://dx.doi.org/10.3748/wjg.v30.i48.5205

Full Article (PDF)	WJG-30-5205-with-cover.pdf
Manuscript File	100804_Auto_Edited_023154.docx
Answering Reviewers	100804-answering-reviewers.pdf
Audio Core Tip	100804-audio.m4a
Conflict-of-Interest Disclosure Form	100804-conflict-of-interest-statement.pdf
Copyright License Agreement	100804-copyright-assignment.pdf
Peer-review Report	100804-peer-reviews.pdf
Scientific Misconduct Check	100804-scientific-misconduct-check.png
Scientific Editor Work List	100804-scientific-editor-work-list.pdf
CrossCheck Report	100804-crosscheck-report.pdf